Core - Gene Expression

Cullen, Bagan R.

Abstract

The purpose of the Gene Expression Facility core component is to provide members of the Proposed Duke CFAR with multi-milligram levels of relevant, biologically active, viral and cellular proteins. The facility anticipates the use of two approaches to achieve this aim, i.e. expression in CHO cells utilizing gene-linked co-amplification and expression in insect cells using baculovirus based expression vectors. In general, secreted and cell surface glycoproteins will be expressed in CHO cells while intracellular proteins will be expressed in insect cells. The use of these higher eukaryotic cells for expression studies will permit the production of biologically active proteins in soluble form, thus facilitating subsequent purification and biological analysis by the investigators involved.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Center Core Grants (P30)
• Project #: 1P30AI028662-01
• Application #: 3815010
• Support Year: 1
• Fiscal Year: 1989

Institution

• Name: Duke University
• DUNS #: 071723621
• City: Durham
• State: NC
• Country: United States
• Zip Code: 27705

Publications

Betts, Michael R; Exley, Barbara; Price, David A et al. (2005) Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A 102:4512-7

Ferrari, Guido; Neal, Wesley; Ottinger, Janet et al. (2004) Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. J Immunol 173:2126-33

Freel, Stephanie A; Fiscus, Susan A; Pilcher, Christopher D et al. (2003) Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. AIDS 17:2025-33

Szczech, L A; Edwards, L J; Sanders, L L et al. (2002) Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57:336-41

Bartlett, John A; Miralles, G Diego; Sevin, Anne D et al. (2002) Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. AIDS Res Hum Retroviruses 18:535-43

Szczech, Lynda Anne; Gange, Stephen J; van der Horst, Charles et al. (2002) Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61:195-202

Pilcher, C D; Shugars, D C; Fiscus, S A et al. (2001) HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 15:837-45

Johnston, A M; Valentine, M E; Ottinger, J et al. (2001) Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. Pediatr Infect Dis J 20:941-6

Tokunaga, K; Greenberg, M L; Morse, M A et al. (2001) Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 75:6776-85

Pilcher, C D; Eron Jr, J J; Vemazza, P L et al. (2001) Sexual transmission during the incubation period of primary HIV infection. JAMA 286:1713-4